$EKSO
EKSO BIONICS HOLDINGS, INC. Stock $ekso

$ekso Overview Financials Valuation SEC Filings Company Website

2019 Q2 Form 10-Q Financial Statement

#000154908419000004 Filed on May 01, 2019

Income Statement

Concept	2019 Q2	2019 Q1	2018 Q1
Revenue	$3.262M	$3.616M	$2.518M
YoY Change	9.94%	43.61%	75.35%
Cost Of Revenue	$1.702M	$2.017M	$1.751M
YoY Change	-14.9%	15.19%	62.58%
Gross Profit	$1.560M	$1.599M	$767.0K
YoY Change	61.32%	108.47%	117.9%
Gross Profit Margin	47.82%	44.22%	30.46%
Selling, General & Admin	$5.159M	$5.127M	$7.591M
YoY Change	-23.68%	-32.46%	35.07%
% of Gross Profit	330.71%	320.64%	989.7%
Research & Development	$1.499M	$1.384M	$1.808M
YoY Change	7.92%	-23.45%	-37.0%
% of Gross Profit	96.09%	86.55%	235.72%
Depreciation & Amortization	$240.0K	$247.0K	$428.0K
YoY Change	-47.83%	-42.29%	-9.89%
% of Gross Profit	15.38%	15.45%	55.8%
Operating Expenses	$6.658M	$6.511M	$9.380M
YoY Change	-18.33%	-30.59%	10.35%
Operating Profit	-$5.098M	-$4.912M	-$8.613M
YoY Change	-29.05%	-42.97%	5.71%
Interest Expense	$107.0K	$121.0K	$163.0K
YoY Change	-33.13%	-25.77%	36.97%
% of Operating Profit
Other Income/Expense, Net	$2.032M	-$1.639M	$712.0K
YoY Change	-356.24%	-330.2%	-1117.14%
Pretax Income	-$3.070M	-$6.550M	-$7.900M
YoY Change	-61.53%	-17.09%	-4.82%
Income Tax
% Of Pretax Income
Net Earnings	-$3.066M	-$6.551M	-$7.899M
YoY Change	-61.57%	-17.07%	-4.85%
Net Earnings / Revenue	-93.99%	-181.17%	-313.7%
Basic Earnings Per Share			-$0.13
Diluted Earnings Per Share	-$651.8K	-$1.509M	-$0.13
COMMON SHARES
Basic Shares Outstanding	67.67M shares	64.26M shares	60.15M shares
Diluted Shares Outstanding			60.15M shares

Balance Sheet

Concept	2019 Q2	2019 Q1	2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$13.26M	$9.240M	$20.57M
YoY Change	-4.54%	-55.08%	118.13%
Cash & Equivalents	$13.26M	$9.236M	$20.57M
Short-Term Investments
Other Short-Term Assets	$610.0K	$510.0K	$960.0K
YoY Change	5.17%	-46.88%	29.73%
Inventory	$3.724M	$3.300M	$2.830M
Prepaid Expenses
Receivables	$4.541M	$3.793M	$3.570M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$22.13M	$16.84M	$27.94M
YoY Change	8.48%	-39.75%	110.68%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.816M	$2.331M	$2.350M
YoY Change	-20.04%	-0.81%	-4.47%
Goodwill	$189.0K	$189.0K
YoY Change	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$168.0K	$140.0K	$120.0K
YoY Change	40.0%	16.67%	30.43%
Total Long-Term Assets	$3.450M	$4.025M	$3.020M
YoY Change	22.99%	33.28%	-16.87%
TOTAL ASSETS
Total Short-Term Assets	$22.13M	$16.84M	$27.94M
Total Long-Term Assets	$3.450M	$4.025M	$3.020M
Total Assets	$25.58M	$20.86M	$30.96M
YoY Change	10.23%	-32.62%	83.25%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.480M	$2.474M	$3.390M
YoY Change	-4.25%	-27.02%	18.24%
Accrued Expenses	$2.768M	$3.286M	$2.760M
YoY Change	-12.46%	19.06%	0.47%
Deferred Revenue	$1.369M	$1.211M
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.333M	$2.333M	$2.333M
YoY Change	0.0%	0.0%	499.74%
Total Short-Term Liabilities	$9.343M	$9.710M	$10.03M
YoY Change	-0.55%	-3.19%	42.86%
LONG-TERM LIABILITIES
Long-Term Debt	$1.535M	$2.093M	$4.290M
YoY Change	-59.02%	-51.21%	-35.34%
Other Long-Term Liabilities	$45.00K	$54.00K	$1.800M
YoY Change	25.0%	-97.0%	1968.97%
Total Long-Term Liabilities	$1.580M	$2.147M	$4.290M
YoY Change	-58.22%	-49.95%	-36.18%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.343M	$9.710M	$10.03M
Total Long-Term Liabilities	$1.580M	$2.147M	$4.290M
Total Liabilities	$20.18M	$16.33M	$16.12M
YoY Change	29.5%	1.28%	-11.81%
SHAREHOLDERS EQUITY
Retained Earnings	-$180.8M	-$177.7M
YoY Change	12.95%
Common Stock	$75.00K	$68.00K
YoY Change	22.95%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$5.404M	$4.534M	$14.84M
YoY Change
Total Liabilities & Shareholders Equity	$25.58M	$20.86M	$30.96M
YoY Change	10.23%	-32.62%	83.25%

Cashflow Statement

Concept	2019 Q2	2019 Q1	2018 Q1
OPERATING ACTIVITIES
Net Income	-$3.066M	-$6.551M	-$7.899M
YoY Change	-61.57%	-17.07%	-4.85%
Depreciation, Depletion And Amortization	$240.0K	$247.0K	$428.0K
YoY Change	-47.83%	-42.29%	-9.89%
Cash From Operating Activities	-$4.530M	-$5.177M	-$6.745M
YoY Change	-25.12%	-23.25%	-7.02%
INVESTING ACTIVITIES
Capital Expenditures	-$50.00K	$7.000K	$31.00K
YoY Change		-77.42%	-77.54%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$50.00K	-$7.000K	-$31.00K
YoY Change		-77.42%	-77.54%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$7.305M	$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	8.600M	$6.769M	-$399.0K
YoY Change	-1557.63%	-1796.49%	-20050.0%
NET CHANGE
Cash From Operating Activities	-4.530M	-$5.177M	-$6.745M
Cash From Investing Activities	-50.00K	-$7.000K	-$31.00K
Cash From Financing Activities	8.600M	$6.769M	-$399.0K
Net Change In Cash	4.020M	$1.581M	-$7.175M
YoY Change	-160.54%	-122.03%	-2.91%
FREE CASH FLOW
Cash From Operating Activities	-$4.530M	-$5.177M	-$6.745M
Capital Expenditures	-$50.00K	$7.000K	$31.00K
Free Cash Flow	-$4.480M	-$5.184M	-$6.776M
YoY Change	-25.95%	-23.49%	-8.33%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2019Q1	dei	Amendment Flag AmendmentFlag	false
CY2019Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2019Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2019Q1	dei	Document Period End Date DocumentPeriodEndDate	2019-03-31
CY2019Q1	dei	Document Type DocumentType	10-Q
CY2019Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001549084
CY2019Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	67669227	shares
CY2019Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2019Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2019Q1	dei	Entity Registrant Name EntityRegistrantName	EKSO BIONICS HOLDINGS, INC.
CY2019Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2019Q1	dei	Trading Symbol TradingSymbol	EKSO
CY2018Q4	ekso	Accrued Clinical Cost Current AccruedClinicalCostCurrent	227000	USD
CY2019Q1	ekso	Accrued Clinical Cost Current AccruedClinicalCostCurrent	273000	USD
CY2018Q1	ekso	Change In Fair Value Contingent Liabilities ChangeInFairValueContingentLiabilities	19000	USD
CY2019Q1	ekso	Change In Fair Value Contingent Liabilities ChangeInFairValueContingentLiabilities	-1000	USD
CY2019Q1	ekso	Class Of Warrant Or Right Expired ClassOfWarrantOrRightExpired	-1504000	shares
CY2018Q1	ekso	Common Stock Contribution CommonStockContribution	56000	USD
CY2019Q1	ekso	Common Stock Contribution CommonStockContribution	55000	USD
CY2019Q1	ekso	Contingent Success Fee Liability ContingentSuccessFeeLiability	35000	USD
CY2019Q1	ekso	Contract With Customer Liability Deferral Of Revenue ContractWithCustomerLiabilityDeferralOfRevenue	561000	USD
CY2019Q1	ekso	Debt Covenant Covenant Compliance Unrestricted Cash DebtCovenantCovenantComplianceUnrestrictedCash	4908000	USD
CY2018Q4	ekso	Deferred Device Revenue DeferredDeviceRevenue	70000	USD
CY2019Q1	ekso	Deferred Device Revenue DeferredDeviceRevenue	36000	USD
CY2018Q4	ekso	Deferred Extended Maintenance And Support DeferredExtendedMaintenanceAndSupport	2114000	USD
CY2019Q1	ekso	Deferred Extended Maintenance And Support DeferredExtendedMaintenanceAndSupport	2281000	USD
CY2018Q4	ekso	Deferred Royalties DeferredRoyalties	300000	USD
CY2019Q1	ekso	Deferred Royalties DeferredRoyalties	300000	USD
CY2018Q1	ekso	Gain Loss On Change In Fair Value Contingent Liabilities GainLossOnChangeInFairValueContingentLiabilities	19000	USD
CY2019Q1	ekso	Gain Loss On Change In Fair Value Contingent Liabilities GainLossOnChangeInFairValueContingentLiabilities	-1000	USD
CY2018Q1	ekso	Gain Loss On Warrant Liability GainLossOnWarrantLiability	732000	USD
CY2019Q1	ekso	Gain Loss On Warrant Liability GainLossOnWarrantLiability	-1122000	USD
CY2018Q1	ekso	Gain Loss On Warrant Modification GainLossOnWarrantModification	0	USD
CY2019Q1	ekso	Gain Loss On Warrant Modification GainLossOnWarrantModification	-257000	USD
CY2019Q1	ekso	Operating Leases Liability Initial Recognition OperatingLeasesLiabilityInitialRecognition	1498000	USD
CY2019Q1	ekso	Operating Leases Rent Expense Annual Incremental Percentage Increase OperatingLeasesRentExpenseAnnualIncrementalPercentageIncrease	0.03
CY2019Q1	ekso	Operating Leases Right Of Use Asset Initial Recognition OperatingLeasesRightOfUseAssetInitialRecognition	1454000	USD
CY2018Q1	ekso	Other Income Expense OtherIncomeExpense	143000	USD
CY2019Q1	ekso	Other Income Expense OtherIncomeExpense	-139000	USD
CY2019Q1	ekso	Proceeds From Issuance Of Common Stock Preference Stock And Warrants ProceedsFromIssuanceOfCommonStockPreferenceStockAndWarrants	2313000	USD
CY2018Q1	ekso	Sales Earnout SalesEarnout	28000	USD
CY2019Q1	ekso	Sales Earnout SalesEarnout	22000	USD
CY2018Q1	ekso	Shares Issued Capital Contribution SharesIssuedCapitalContribution	508000	USD
CY2019Q1	ekso	Shares Issued Capital Contribution SharesIssuedCapitalContribution	191000	USD
CY2018Q1	ekso	Stock Issued During Period Value Equiposis Supply And Sales Earnouts StockIssuedDuringPeriodValueEquiposisSupplyAndSalesEarnouts	28000	USD
CY2019Q1	ekso	Stock Issued During Period Value Equiposis Supply And Sales Earnouts StockIssuedDuringPeriodValueEquiposisSupplyAndSalesEarnouts	22000	USD
CY2016Q4	ekso	Success Fee Expenses SuccessFeeExpenses	250000	USD
CY2018Q1	ekso	Transfer Of Property And Equipment From Inventory TransferOfPropertyAndEquipmentFromInventory	348000	USD
CY2019Q1	ekso	Transfer Of Property And Equipment From Inventory TransferOfPropertyAndEquipmentFromInventory	206000	USD
CY2019Q1	ekso	Unrestricted Cash UnrestrictedCash	4328000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3156000	USD
CY2019Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2474000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3660000	USD
CY2019Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3793000	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3541000	USD
CY2019Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3286000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-92000	USD
CY2019Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	56000	USD
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	173903000	USD
CY2019Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	182107000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	830000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	636000	USD
CY2018Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	892000	USD
CY2019Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	636000	USD
CY2018Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	128000	USD
CY2019Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	179000	USD
CY2019Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	67529000	shares
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	63000	USD
CY2018Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6419000	shares
CY2019Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8262000	shares
CY2018Q4	us-gaap	Assets Assets	17655000	USD
CY2019Q1	us-gaap	Assets Assets	20860000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	14967000	USD
CY2019Q1	us-gaap	Assets Current AssetsCurrent	16835000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27813000	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20572000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7655000	USD
CY2019Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9236000	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-7241000	USD
CY2019Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1581000	USD
CY2018Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	3396000	shares
CY2019Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1892000	shares
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	141429000	shares
CY2019Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	141429000	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	62963000	shares
CY2019Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	67529000	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	62963000	shares
CY2019Q1	us-gaap	Common Stock Value CommonStockValue	68000	USD
CY2018Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8108000	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6403000	USD
CY2018Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2597000	USD
CY2019Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2710000	USD
CY2018Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1102000	USD
CY2019Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1211000	USD
CY2018Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1495000	USD
CY2019Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1499000	USD
CY2019Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	448000	USD
CY2019Q1	us-gaap	Contractual Obligation ContractualObligation	1221000	USD
CY2019Q1	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	50000	USD
CY2018Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1751000	USD
CY2019Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2017000	USD
CY2018Q4	us-gaap	Customer Advances And Deposits CustomerAdvancesAndDeposits	62000	USD
CY2019Q1	us-gaap	Customer Advances And Deposits CustomerAdvancesAndDeposits	55000	USD
CY2019Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	4523000	USD
CY2019Q1	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.1047
CY2019Q1	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	-97000	USD
CY2018Q4	us-gaap	Deferred Rent Credit DeferredRentCredit	51000	USD
CY2019Q1	us-gaap	Deferred Rent Credit DeferredRentCredit	38000	USD
CY2018Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1102000	USD
CY2019Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1211000	USD
CY2018Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	1495000	USD
CY2019Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	1499000	USD
CY2018	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.5
CY2018Q1	us-gaap	Depreciation Depreciation	428000	USD
CY2019Q1	us-gaap	Depreciation Depreciation	247000	USD
CY2018Q1	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	43000	USD
CY2019Q1	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	28000	USD
CY2018Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	585000	USD
CY2019Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	1964000	USD
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.13
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.10
CY2018Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-66000	USD
CY2019Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-4000	USD
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2446000	USD
CY2019Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2458000	USD
CY2018Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	35000	USD
CY2019Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	36000	USD
CY2018Q1	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	153000	USD
CY2019Q1	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-152000	USD
CY2018Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3738000	USD
CY2019Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2317000	USD
CY2018Q4	us-gaap	Goodwill Goodwill	189000	USD
CY2019Q1	us-gaap	Goodwill Goodwill	189000	USD
CY2018Q1	us-gaap	Gross Profit GrossProfit	767000	USD
CY2019Q1	us-gaap	Gross Profit GrossProfit	1599000	USD
CY2018Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	16000	USD
CY2019Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1011000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-660000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	798000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	188000	USD
CY2018Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	80000	USD
CY2019Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-167000	USD
CY2018Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	141000	USD
CY2019Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	113000	USD
CY2018Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	286000	USD
CY2019Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	154000	USD
CY2018Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-379000	USD
CY2019Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	142000	USD
CY2018Q1	us-gaap	Interest Expense InterestExpense	163000	USD
CY2019Q1	us-gaap	Interest Expense InterestExpense	121000	USD
CY2019Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	20860000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10132000	USD
CY2019Q1	us-gaap	Liabilities Current LiabilitiesCurrent	9710000	USD
CY2019Q1	us-gaap	Long Term Debt LongTermDebt	4426000	USD
CY2019Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	2333000	USD
CY2018Q1	us-gaap	Interest Paid Net InterestPaidNet	119000	USD
CY2019Q1	us-gaap	Interest Paid Net InterestPaidNet	96000	USD
CY2018Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	730000	USD
CY2019Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	335000	USD
CY2018Q4	us-gaap	Inventory Gross InventoryGross	3737000	USD
CY2019Q1	us-gaap	Inventory Gross InventoryGross	3605000	USD
CY2018Q4	us-gaap	Inventory Net InventoryNet	3371000	USD
CY2019Q1	us-gaap	Inventory Net InventoryNet	3300000	USD
CY2018Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	2676000	USD
CY2019Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	2967000	USD
CY2018Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	366000	USD
CY2019Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	305000	USD
CY2018Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	331000	USD
CY2019Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	303000	USD
CY2018Q1	us-gaap	Inventory Write Down InventoryWriteDown	130000	USD
CY2019Q1	us-gaap	Inventory Write Down InventoryWriteDown	19000	USD
CY2019Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	0	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1782000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	0	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	261000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	564000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	551000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	406000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	370000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2019Q1	us-gaap	Lessor Operating Lease Term Of Contract LessorOperatingLeaseTermOfContract	P12M
CY2018Q4	us-gaap	Liabilities Liabilities	14927000	USD
CY2019Q1	us-gaap	Liabilities Liabilities	16326000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	17655000	USD
CY2019Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	440000	USD
CY2019Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	2333000	USD
CY2019Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	1750000	USD
CY2019Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2093000	USD
CY2018Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	2648000	USD
CY2019Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	2093000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-399000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6769000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-31000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6745000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5177000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-7901000	USD
CY2018Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	USD
CY2019Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1639000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-6551000	USD
CY2018Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7901000	USD
CY2019Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6551000	USD
CY2018Q4	us-gaap	Notes Payable Current NotesPayableCurrent	2333000	USD
CY2019Q1	us-gaap	Notes Payable Current NotesPayableCurrent	2333000	USD
CY2019Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2018Q1	us-gaap	Operating Expenses OperatingExpenses	9380000	USD
CY2019Q1	us-gaap	Operating Expenses OperatingExpenses	6511000	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-8613000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4912000	USD
CY2019Q1	us-gaap	Operating Lease Lease Income OperatingLeaseLeaseIncome	815000	USD
CY2019Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1412000	USD
CY2018Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0	USD
CY2019Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	406000	USD
CY2018Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2019Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1006000	USD
CY2019Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1365000	USD
CY2019Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.105
CY2019Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y2M
CY2018Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	143000	USD
CY2019Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	140000	USD
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	256000	USD
CY2019Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	114000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	134000	USD
CY2019Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	140000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-207000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	148000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-207000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	148000	USD
CY2018Q4	us-gaap	Other Employee Related Liabilities Current OtherEmployeeRelatedLiabilitiesCurrent	270000	USD
CY2019Q1	us-gaap	Other Employee Related Liabilities Current OtherEmployeeRelatedLiabilitiesCurrent	116000	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	67000	USD
CY2019Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	54000	USD
CY2018Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	712000	USD
CY2018Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	31000	USD
CY2019Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7000	USD
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2019Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2019Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	281000	USD
CY2019Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	506000	USD
CY2018Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2019Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	7305000	USD
CY2018Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2019Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	55000	USD
CY2018Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	307000	USD
CY2019Q1	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	289000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2365000	USD
CY2019Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2331000	USD
CY2018Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-16000	USD
CY2019Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	55000	USD
CY2018Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	399000	USD
CY2019Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	591000	USD
CY2018Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1808000	USD
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1384000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-171146000	USD
CY2019Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-177697000	USD
CY2018Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2518000	USD
CY2019Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	3616000	USD
CY2019Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	764000	USD
CY2019Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	788000	USD
CY2019Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	1103000	USD
CY2019Q1	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P9M
CY2019Q1	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2019Q1	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
CY2018Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3853000	USD
CY2019Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2809000	USD
CY2018Q1	us-gaap	Share Based Compensation ShareBasedCompensation	892000	USD
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	636000	USD
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.88
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.03
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0274
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0245
CY2017Q4	us-gaap	Share Price SharePrice	8.00
CY2018Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
CY2019Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2018Q1	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	190000	USD
CY2018Q1	us-gaap	Stock Issued1 StockIssued1	190000	USD
CY2019Q1	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	508000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	191000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	7305000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	55000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	21391000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	14839000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	2728000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	4534000	USD
CY2018Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	60146000	shares
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	65067000	shares
CY2019Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Concentration of Credit Risk and Other Risks and Uncertainties</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and accounts receivable. The Company maintains its cash accounts in excess of federally insured limits. However, the Company believes it is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held. The Company extends credit to customers in the normal course of business and performs ongoing credit evaluations of its customers. Concentrations of credit risk with respect to accounts receivable exist to the full extent of amounts presented in the condensed consolidated financial statements. The Company does not require collateral from its customers to secure accounts receivable.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable are derived from the sale of products shipped to and services performed for customers. Invoices are aged based on contractual terms with the customer. The Company reviews accounts receivable for collectability and records an allowance for credit losses, as needed. The Company has not experienced any material losses related to accounts receivable as of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Many of the sales contracts with customers outside of the U.S. are settled in a foreign currency. The Company does not enter into any foreign currency hedging agreements and is susceptible to gains and losses from foreign currency fluctuations. To date, the Company has not experienced significant gains or losses upon settling foreign currency denominated accounts receivable.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company had no customers with an accounts receivable balance totaling </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;"> or more of the Company’s total accounts receivable compared with one customer as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> (</font><font style="font-family:inherit;font-size:10pt;">19%</font><font style="font-family:inherit;font-size:10pt;">).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the </font><font style="font-family:inherit;font-size:10pt;">three months ended March 31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, the Company had one customer with sales of </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;"> or more of the Company’s total revenue (</font><font style="font-family:inherit;font-size:10pt;">11%</font><font style="font-family:inherit;font-size:10pt;">).</font></div></div>
CY2019Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet, and the reported amounts of revenues and expenses during the reporting period. For the Company, these estimates include, but are not limited to: revenue recognition, deferred revenue and the deferral of the associated costs, future warranty costs, accounting for leases, useful lives assigned to long-lived assets, valuation of inventory, realizability of deferred tax assets, the valuation of employee stock options and warrants, and contingencies. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001549084-19-000004-index-headers.html	Edgar Link	pending
0001549084-19-000004-index.html	Edgar Link	pending
0001549084-19-000004.txt	Edgar Link	pending
0001549084-19-000004-xbrl.zip	Edgar Link	pending
ekso-20190331.xml	Edgar Link	completed
ekso-20190331.xsd	Edgar Link	pending
ekso-20190331_cal.xml	Edgar Link	unprocessable
ekso-20190331_def.xml	Edgar Link	unprocessable
ekso-20190331_lab.xml	Edgar Link	unprocessable
ekso-20190331_pre.xml	Edgar Link	unprocessable
ekso-33119x10q.htm	Edgar Link	pending
ekso-33119xex101.htm	Edgar Link	pending
ekso-33119xex102.htm	Edgar Link	pending
ekso-33119xex311.htm	Edgar Link	pending
ekso-33119xex312.htm	Edgar Link	pending
ekso-33119xex321.htm	Edgar Link	pending
ekso-33119xex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EKSO
EKSO BIONICS HOLDINGS, INC. Stock $ekso

2019 Q2 Form 10-Q Financial Statement

#000154908419000004 Filed on May 01, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EKSO EKSO BIONICS HOLDINGS, INC. Stock $ekso

2019 Q2 Form 10-Q Financial Statement

#000154908419000004 Filed on May 01, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EKSO
EKSO BIONICS HOLDINGS, INC. Stock $ekso